Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

Published:2024-07-26 Issue:1 Volume:22 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Wang Yu,Xue Yu-juan,Zuo Ying-xi,Jia Yue-ping,Lu Ai-dong,Zeng Hui-min,Zhang Le-ping

Funder

the Foundation of 2018 Beijing Key Clinical Specialty Construction Project-Pediatrics

the National Natural Science Foundation of China

Peking University People’s Hospital Scientific Research Development Funds

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12967-024-05362-w.pdf

Reference3 articles.

1. Li W, Ding L, Shi W, et al. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. J Transl Med. 2023;21(1):213.

2. Wudhikarn K, Flynn JR, Rivière I, et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021;138(7):531–43.

3. Schultz LM, Eaton A, Baggott C, et al. Outcomes after nonresponse and Relapse Post-tisagenlecleucel in Children, adolescents, and young adults with B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023;41(2):354–63.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP